Investing in Phathom Pharmaceuticals Inc. (PHAT) Is Getting More Attractive


In a filing, Phathom Pharmaceuticals Inc. revealed its CFO and CBO Henderson Molly unloaded Company’s shares for reported $22368.0 on Jun 02. In the deal valued at $11.41 per share,1,960 shares were sold. As a result of this transaction, Henderson Molly now holds 68,506 shares worth roughly $ 0.99 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Henderson Molly sold 2,110 shares, generating $27,165 in total proceeds. Upon selling the shares at $12.87, the CFO and CBO now owns 70,466 shares.

Before that, Nabulsi Azmi bought 10,000 shares. Phathom Pharmaceuticals Inc. shares valued at $82,600 were divested by the Chief Operating Officer at a price of $8.26 per share. As a result of the transaction, Nabulsi Azmi now holds 99,567 shares, worth roughly $1.45 million.

H.C. Wainwright initiated its Phathom Pharmaceuticals Inc. [PHAT] rating to a Buy in a research note published on Friday, August 09, 2023; the price target was $28. PT values the company’s stock at a premium of 48.14 to its Friday closing price.

Price Performance Review of PHAT

On Friday, Phathom Pharmaceuticals Inc. [NASDAQ:PHAT] saw its stock jump 0.90% to $14.52. On the same session, the stock had its day’s lowest price of $14.02, but rose to a high of $14.698. Over the last five days, the stock has gained 0.62%. Phathom Pharmaceuticals Inc. shares have risen nearly 29.41% since the year began. Nevertheless, the stocks have risen 70.02% over the past one year. While a 52-week high of $17.02 was reached on 08/11/23, a 52-week low of $5.84 was recorded on 03/24/23. SMA at 50 days reached $14.34, while 200 days put it at $11.15. A total of 0.33 million shares were traded, compared to the trading of 0.27 million shares in the previous session.

Levels Of Support And Resistance For PHAT Stock

The 24-hour chart illustrates a support level at 14.13, which if violated will result in even more drops to 13.73. On the upside, there is a resistance level at 14.81. A further resistance level may holdings at 15.09. The Relative Strength Index (RSI) on the 14-day chart is 48.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.51%. Stochastics %K at 17.49% indicates the stock is a buying.

How much short interest is there in Phathom Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Phathom Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -1.71 million shares to a total of 2.59 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 4.3 million shares. There was a decline of -66.02%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 6.63% of the overall stock float, the days-to-cover ratio (short ratio) fell to 9.12.

Phathom Pharmaceuticals Inc. [PHAT] – Who Are The Largest Shareholders?

In filings from Invesco Advisers, Inc., it is revealed that the company now owns 3,152,920 shares, or roughly 5.76% of the outstanding PHAT shares. In other words, the investor’s shares have risen by 1,084,494 from its previous 13-F filing of 2068426.0. Additionally, Avidity Partners Management LP decreased -4.83% of its stake after which the total value it holdings stand at $29,654,937, while BlackRock Fund Advisors added 21.99% of its stake to hold $26.85 million in the firm. Over the last quarter, Ensign Peak Advisors, Inc. sold -4,064 shares of Phathom Pharmaceuticals Inc., while The Vanguard Group, Inc. sold 573,842 shares. At present, 683 Capital Management LLC is holding 1,287,500 shares valued at $19.58 million. Gilder, Gagnon, Howe & Co. LLC owned 1,060,605 shares of the company at the time of its most recent 13F filing, worth $16.13 million.

According to FactSet, Phathom Pharmaceuticals Inc.’s share price will average $21.86 in the next year, based on opinions of analysts polled by the firm. This is up nearly 59.83 percent from its previous closing price of $14.39. Analysts expect Phathom Pharmaceuticals Inc. stock to reach the higher price of $28.00, while the lowest price estimate is $9.00. However, 7 analysts have rated PHAT stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here